Biohaven (NYSE:BHVN) Shares Up 9.6% - Still a Buy?

Biohaven logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Biohaven shares rose 9.6% to $14.135, although trading volume was 89% below its average.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $21.14; recent targets range widely, including $10 from HC Wainwright and $48 from Robert W. Baird.
  • Institutional investors own 88.78% of the shares. Biohaven is a clinical-stage biotech with investigational treatments and no marketed products.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) traded up 9.6% on Thursday. The company traded as high as $13.94 and last traded at $14.1350. 295,513 shares changed hands during trading, a decline of 89% from the average session volume of 2,742,931 shares. The stock had previously closed at $12.90.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Royal Bank Of Canada lifted their price target on Biohaven from $19.00 to $22.00 and gave the stock a "sector perform" rating in a research report on Friday, October 23rd. HC Wainwright reissued a "neutral" rating and issued a $10.00 price objective on shares of Biohaven in a report on Thursday, September 10th. Robert W. Baird set a $48.00 price objective on shares of Biohaven in a research note on Thursday, October 22nd. Canaccord Genuity Group increased their price target on Biohaven from $21.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. Finally, Morgan Stanley lifted their price objective on Biohaven from $19.00 to $21.00 and gave the company an "overweight" rating in a research note on Tuesday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $21.14.

Check Out Our Latest Research Report on Biohaven

Biohaven Stock Up 8.6%

The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 21.23. The company has a market capitalization of $2.12 billion, a PE ratio of -3.64 and a beta of 1.36. The business has a fifty day moving average of $13.41 and a 200 day moving average of $12.37.

Institutional Trading of Biohaven

Institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its position in Biohaven by 52.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 202,975 shares of the company's stock valued at $1,717,000 after buying an additional 69,894 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Biohaven in the 1st quarter valued at approximately $1,362,000. Janus Henderson Group PLC boosted its position in shares of Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock worth $148,214,000 after purchasing an additional 16,127,247 shares in the last quarter. Quantinno Capital Management LP increased its holdings in shares of Biohaven by 190.0% in the 1st quarter. Quantinno Capital Management LP now owns 121,554 shares of the company's stock valued at $1,028,000 after purchasing an additional 79,640 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in shares of Biohaven in the second quarter valued at about $196,574,000. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies. The company's pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biohaven Right Now?

Before you consider Biohaven, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.

While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines